Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients

Aoyama, Toru; Yoshikawa, Takaki; Watanabe, Takafumi; Hayashi, Tsutomu; Ogata, Takashi; Cho, Haruhiko; Tsuburaya, Akira

doi:10.1007/s10120-011-0068-7

Cited by 11 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed that patients aged ≥60 years had a survival trend similar to that of patients aged <60 years in different treatment groups, providing further evidence that age does not impact the efficacy of adjuvant therapy in gastric cancer [18], [19]. Female patients who received six cycles failed to show a significant survival benefit compared with those who received four and eight cycles, however, six cycles was associated with a trend toward better survival.…”

Section: Discussionsupporting

confidence: 60%

Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundAlthough several clinical trials have suggested that postoperative adjuvant chemotherapy can improve survival of patients with gastric cancer, the optimal treatment duration has not been studied. This retrospective analysis evaluated the outcomes of patients with gastric cancer treated with six cycles of fluorouracil-based treatment compared with a cohort treated with four or eight cycles.MethodsWe retrospectively identified 237 patients with stage IB–IIIC gastric cancer who received four, six, or eight cycles of fluorouracil-based adjuvant chemotherapy administered every 3 weeks after radical gastrectomy. The endpoint was overall survival (OS). Factors associated with prognosis were also analyzed.ResultsThe estimated 3-year OS rates for the four-, six-, and eight-cycle cohorts were 54.4%, 76.1%, and 68.9%, respectively; and the estimated 5-year OS rates were 41.2%, 74.0%, and 65.8%, respectively. Patients who received six cycles were more likely to have a better OS than those who received four cycles (P = 0.002). Eight cycles failed to show an additional survival benefit (P = 0.454). In the multivariate analysis, the number of chemotherapy cycles was associated with OS independent of clinical covariates (P<0.05). Subgroup analysis suggested that among patients in all age groups examined, male patients, and subgroups of fluorouracil plus oxaliplatin combined chemotherapy, stage III, poor differentiation, and gastrectomy with D2 lymphadenectomy, six cycles of adjuvant chemotherapy were associated with a statistically significant benefit of OS compared with four cycles (P<0.05).ConclusionsSix cycles of adjuvant chemotherapy might lead to a favorable outcome for patients with gastric cancer, and two further cycles could not provide an additional clinical benefit.

show abstract

Section: Discussionsupporting

confidence: 60%

Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…2 and 3). Aoyama et al (19) reported that in gastric cancer no difference was observed in the RDI of the adjuvant chemotherapy with S-1 in older (≥70 years old) and younger (<70 years old) patients with gastrectomy. However, Tsushima et al (20) demonstrated that median RDI in younger (≤65 years old) patients was likely to be lower compared to older (>65 years old) patients, including patients with unresectable gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer

Okumura

Sasaki

Satoh

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The efficacy of adjuvant chemotherapy with S-1 in patients with completely resected non-small cell lung cancer (NSCLC) has yet to be clarified, and the appropriate schedule for the adjuvant chemotherapy with S-1 remains unknown. A phase II study was conducted to evaluate the feasibility and efficacy of adjuvant chemotherapy with S-1. Patients enrolled in this study were 20-75 years old, had pathological stage IB-IIIA NSCLC, and had received complete resection of NSCLC. S-1 (80 mg/m 2 ) was administered orally to the patients for four weeks followed by a two-week rest period (conventional schedule), for a maximum of eight cycles. The primary endpoint was relative dose intensity (RDI), while the secondary endpoints were safety and 1 year of disease-free survival (1y-DFS). Between

show abstract

“…A phase III clinical trial of adjuvant chemotherapy and chemotherapy for unresectable gastric cancer was performed, but patients aged 80 and over were excluded . Aoyama et al reported that the incidences of grade III hematological and non‐hematological toxicities of S‐1 adjuvant chemotherapy for the elderly were <5%, and that this regimen was safe and feasible and Tsushima et al reported that S‐1 or S‐1 plus cisplatin for elderly patients presented a high risk of hematological toxicities, but was feasible. However, there were only a few patients aged 80 and older in these studies.…”

Section: Discussionmentioning

confidence: 99%

The outcome of surgical treatment for elderly patients with gastric carcinoma

Sakurai

Muguruma

Nagahara

et al. 2015

Journal of Surgical Oncology

View full text Add to dashboard Cite

BackgroundThe aim of this study was to clarify the operative mortality and long‐term survival of gastrectomy for elderly patients with gastric cancer.MethodsA total of 461 patients who underwent gastrectomy for gastric cancer in our hospital were classified as elderly group (≥80 years‐old, 95 patients) and control group (60–69 years‐old, 366 patients).ResultsThe frequency of comorbidities was significantly (P < 0.05) higher in elderly group (74.7%) than that in the control group (49.5%). No significant difference of the postoperative complication rate was found between the elderly group (23.2%) and the control group (23.2%). Adjuvant chemotherapy was 9.5% in the elderly group, which was significantly less than 29.0% of the control group (P < 0.05). Stage II and III elderly patients had worse disease specific survival (DSS) than controls did. In the elderly, overall survival (OS) was significantly worse than DSS in stage I patients (P < 0.05).ConclusionsThe operative complication rate of elderly patients was comparable to the control group. Comorbidity and occurrence of secondary malignant disease should be followed for elderly patients at stage I. For stage II and III disease patients, a novel drug which is acceptable for the elderly is needed as a postoperative therapy. J. Surg. Oncol. 2015 111:848–854. © 2015 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc.

show abstract

Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients

Cited by 11 publications

References 10 publications

Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer

Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer

Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer

The outcome of surgical treatment for elderly patients with gastric carcinoma

Contact Info

Product

Resources

About